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1. Introduction 
Drug induced hepatotoxicity can be defined as a liver injury caused by drug or herbal 
medicines leading to liver test abnormalities or to a liver dysfunction with a reasonable 
exclusion of the other competing aetiologies. The liver has a central function in the 
metabolism of the xenobiotics, and as a result it may be susceptible to its toxic or 
idiosyncratic effects. While the overall incidence of drug induced liver injury (DILI) is 
infrequent (1 in 10.000 to 100.000 persons exposed), the impact is significant in the general 
population, with broad implications for patients, physicians, pharmaceutical industries 
and governmental regulatory agencies. DILI is the principle reason for the termination in 
clinical trials and the most frequent adverse event leads to drug non approvals, 
withdrawals or to a restriction of prescription drug use after an initial approval and post-
marketing regulatory decisions. DILI has been shown to have a dose-dependent 
component. However, most of the cases of DILI are due to idiosyncratic reactions: over 
1000 drugs and herbal products have been associated with idiosyncratic hepatotoxicity. It 
is difficult to establish a diagnosis of DILI. In fact, there is no single pathognomonic test to 
establish that a given drug in a given subject is the cause of liver injury. Furthermore, the 
clinical presentation of DILI may considerably vary. It can mimic other known forms of 
acute and chronic liver diseases and the severity may range from asymptomatic elevations 
of hepatic enzymes to fulminant hepatic failure. Because of these factors, a diagnosis of 
DILI is frequently delayed or may be entirely missed. So, the study of DILI is confounded 
by the heterogeneity of its clinical presentation and by the course of the injury, the delay 
in establishing diagnosis as it requires exclusion of other causes of liver injury, the lack of 
standardized criteria or specific ‘gold standard’ diagnostic tests and underreporting of 
cases of DILI or their final outcomes. The aim of this chapter is to provide a review and an 
update of DILI. 
2. Epidemiology 
Internationally, the data on the true incidence of DILI in the general population remain 
unknown because of the several methodological limitations of the reporting systems. 
Most of the epidemiological studies are retrospective and lack standardized diagnostic 
work-up to exclude other potential causes of the liver injury. Moreover, most studies 
originate from tertiary referral centres and suffer from selection bias.  The underreporting 
of adverse drug reactions is well known and DILI is not an exception. The number of 
www.intechopen.com
 Liver Biopsy in Modern Medicine 
 
118 
included patients in most of the clinical drug trials is less than 10.000 and hepatotoxicity 
has been mostly detected in the post-marketing phase. According to reporting systems, 
the incidence in the general population varies between 1.27 per 100.000 person a year in 
rural England to 2.4 in Spain and Sweden. Among medical inpatients, the incidence is 1.4 
%, whereas in an outpatient setting it is 0.014 % for patient a year. In the United States 
(USA), approximately 2000 the cases of acute liver failure (ALF) occur annually and drugs 
account for over 50% of them (39% are due to acetaminophen, 13% are idiosyncratic 
reactions due to other medications). Drugs account for 2-5% of cases of patients 
hospitalized with jaundice and approximately 10% of all the cases of acute hepatitis. 
However, these numbers are likely underestimated. The epidemiology of DILI is 
influenced by geographic and cultural factors. In Western countries, the majority of cases 
are associated with antibiotics and psychotropic agents. In the USA, for instance, 
amoxicillin/clavulanate, isoniazid, nitrofurantoin and fluoroquinolones are the most 
frequent causes of DILI. In Asian countries, herbal and dietary supplements rather than 
conventional medications are often the most common causes of DILI; herbals/dietary 
supplements currently represent less than 10% of the cases of DILI in Western countries, 
although this proportion seems to increase. In the last few years, the USA Food and Drug 
Administration (FDA) have withdrawn two drugs from the market for causing severe 
liver injury: bromfenac and troglitazone. Bromfenac, a non-steroidal anti-inflammatory 
drug (NSAID), was introduced in 1997 as a short-term analgesic for orthopedic patients. 
Although approved for a dosing period of less than 10 days, patients used it for longer 
periods. This resulted in more than 50 cases of severe hepatic injury, and the drug had to 
be withdrawn in 1998. Troglitazone is a thiazolidinedione and was approved in 1997 as an 
antidiabetic agent. Over 3 years, more than 90 cases of hepatotoxicity were reported, 
which resulted in a withdrawal of this drug. Kava kava, an herb used for anxiety, was 
reported as being hepatotoxic and was withdrawn from the German market. The FDA has 
also issued a warning in this country. This demonstrates the importance of a post-
marketing surveillance to identify reactions that are not reported or are underreported in 
drug trials. Pemoline, used for attention deficit disorder and narcolepsy is no longer 
available in the USA. The FDA concluded that the overall risk of liver toxicity from 
pemoline outweighs the benefits. Other drugs having significant use limitations because 
of their hepatotoxic effects are felbamate, an antiepileptic used for complex partial 
seizures; zileuton, indicated for asthma; tolcapone, used for Parkinson’s disease; 
trovafloxacin, an antibiotic; benoxaprofen, a NSAID and tienilic acid, a diuretic. 
3. Mechanism of hepatotoxicity 
The liver is the principal organ for metabolism and elimination of many drugs. The majority 
of oral drugs and xenobiotics are lipophilic and water-insoluble, enabling easy absorption 
across cell intestinal membranes. They are rendered hydrophilic via hepatic metabolism and 
thus more easily excreted. Exogenous products are metabolized in the liver mainly through 
phase I and II reactions. The products are then excreted on either the canalicular and 
sinusoidal membranes (phase III reactions). During phase I metabolism, polar groups are 
added to lipophilic molecules by oxidation, reduction or hydrolysis to increase water-
solubility. This group of reactions is catalyzed by a super family of enzymes located in the 
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smooth endoplasmic reticulum, known as cytochrome P450 (mixed function oxidases). 
These membrane-bound hemoproteins carry out reactions in concert with nicotinamide 
adenine dinucleotid phosphate (NADPH) as a source of electrons, so they can generate toxic 
electrophilic chemicals and free radicals. Following phase I metabolism, most compounds 
are still insufficiently hydrophilic for excretion and require further processing. Phase II 
reactions result in the formation of readily excretable, nontoxic substances. The drug or its 
metabolite are conjugated in cytosol to a large water-soluble polar group, such as 
glutathione (GSH), glucuronic acid, sulfate, glucuronide. The enzymes responsible for this 
so-called phase II metabolism are glucuronosyl transferases, sulfotransferases and GSH 
transferases. Phase III reactions lead to the transport of drugs and metabolites out of 
hepatocytes. Biliary excretion is mediated by ATP-dependent transporters located in the bile 
canaliculi. Altered activity of these transporters can lead to hepatotoxicity. Genetic 
polymorphisms or environmental factors, such as concomitant drugs and alcohol, can 
account for differences in phase I, II and III drug metabolism among individuals and may be 
determinants of the susceptibility to DILI by influencing the hepatic exposure to toxic 
metabolites.  
3.1 Mechanisms of injury 
The drugs can directly have an effect on the cellular biochemistry or elicit an immune 
reaction. In most of the instances, the bioactivation of drug to chemically reactive 
metabolites or free radicals promote some chemical reactions (i.e. depletion of reduced 
glutathione and/or covalent bind intracellular macromolecules) leading to their changes. 
The reactive metabolites may induce the mitochondrial dysfunction resulting in a 
decrease in ATP levels; the consequential disassembly of the actin fibrils on the surface of 
the hepatocyte causes blebs and rupture of the membrane. Furthermore, toxic metabolites 
influence the transport of proteins through the canalicular membrane with the 
interruption of the bile flow. The stoppage of the transport pumps such as a multidrug 
resistance (MDR)-associated protein 3 prevents the excretion of bilirubin, causing 
cholestasis. Alternatively, the drugs/metabolites have the capacity to initiate 
immunological reactions, including both innate and adaptive immune responses. 
Hepatocyte stress and/or damage could result in the activation of the innate immune 
system. Natural killer (NK)-NKT cells in the liver modulate the innate immune response 
by secreting interferon (IFN)-gamma, interleukin (IL)-4, and so directly killing the cells by 
FasL expression. Kupffer cells, NK and NKT cells contribute to the progression of liver 
injury by producing pro-inflammatory mediators such as cytokines, chemokines, reactive 
oxygen intermediates and reactive nitrogen intermediates. These pro-inflammatory 
mediators can be directly cytotoxic (e.g., hydrogen peroxide, nitric oxide, peroxynitrite) 
and degrade the extracellular matrix (e.g., collagenase, elastase); furthermore they 
promote a cell adhesion and infiltration (e.g., IL-1, tumor necrosis factor-alpha, 
chemokines). In addition, the adaptive immune system is activated and involved in the 
pathogenesis of the liver injury. The reactive metabolite may covalently bind to or alter 
the liver proteins, such as cytochrome P450 enzymes, activating cytotoxic T cells and 
cytokines (immune-mediated injury). The mechanism of the immune-mediated drug 
reaction is not clear, but it may involve a hapten-like action. Generally, the low-molecular-
weight organic chemicals are not immunogenic, but may become such when they are 
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bound to a macromolecule, such as a protein. If a drug metabolite produced by 
cytochrome P450 is able to act as a hapten, it covalently binds to a liver protein, so it will 
perceive as foreign by the immune system, resulting in an autoimmune attack on the 
normal hepatocellular constituents. This hypothesis, however, does not explain many 
aspects of immune-mediated DILI. For instance, covalent binding (haptenation) is a 
regular occurrence with drugs, such as halothane, that rarely cause an immune-mediated 
toxicity. It is possible that a reactive metabolite also has to injure or stress the liver cells, in 
addition to a modification of a protein, and may cause an immune response. The outcome 
of the events initiated by toxic metabolites either directly affecting the cellular 
biochemistry or inducing immune-mediated response is the cell death. The mode of the 
cell death may be apoptosis or necrosis. Apoptosis involves shrinkage, organelles 
compaction, nuclear condensation and fragmentation of the cell into smaller bodies with 
the intact plasma membranes. The apoptotic cells are then rapidly removed by 
phagocytosis. Necrosis is characterized by a cell swelling and a membrane lysis with a 
release of the cytoplasmic contents. Apoptosis generally represents the activation of an 
enzyme-mediated autolytic cell disposal system, whereas necrosis represents a loss of 
osmotic regulation. Apoptosis results from the activation of a family of highly conserved 
proteases (caspases) through a membrane-associated death receptor. The drugs that alter 
the expression and function of the death receptors disrupt the mitochondrial functions 
and can be expected to activate apoptosis. If apoptosis occurs at a rate that exceeds the 
capacity of the phagocytic cells to remove the apoptotic cells, large fields of contiguous 
cells will swell and lyze. The selection between apoptosis versus necrosis depends on 
several factors, involving the ATP status. A more severe injury to mitochondria leads to a 
cellular energetic impaired; as a consequence the osmotic regulation is lost and the cell 
undergoes to swelling and lysis (necrosis), whereas a less severe injury to mitochondria 
without a profound ATP depletion can maintain the osmotic regulation and undergo to 
apoptosis. Hepatocyte death is the main event that leads to a liver injury, although the 
sinusoidal endothelial cells or the bile duct epithelium may also be targets. 
4. Classification 
DILI can be classified according to the clinical presentation and the laboratory features, the 
mechanism of toxicity and/or the histological findings (see section 5). 
4.1 Clinical pattern 
A consensus defined the liver injury as an increase of more than twice the upper limit of the 
normal range (ULN) in the levels of serum alanina aminotransferase (ALT) or alkaline 
phosphatase (Alk P) and total bilirubin, providing that one of these was more than twice the 
ULN. The Council for International Organizations of Medical Sciences (CIOMS) developed a 
series of standard designations of DILI and a classification of the injuries. According to 
these, the pattern distinction is based on the ratio of serum ALT results to Alk P with respect 
to their ULN. A ratio > 5 denotes an hepatocellular injury and a ratio < 2 denotes a 
cholestatic injury. Ratios between 2 and 5 are categorized as mixed. In the case in which 
ALT or Alk P are elevated before the medicine is started, the baseline values can be taken 
into account instead of the ULN. 
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Type of injury 
 Hepatocellular Cholestatic Mixed 
ALT > twice normal normal > twice normal 
Alk P normal > twice normal > twice normal 
ALT/Alk P ≥ 5 ≤ 2 2 – 5 
 Acetaminophen 
Allopurinol 
Amiodarone 
Amoxicillin–
clavulanic acid 
Baclofen 
Herbals: kava kava 
and germander 
Isoniazid 
Ketoconazole 
Lisinopril 
Losartan 
Methotrexate 
NSAIDs 
Omeprazole 
Paroxetine 
Rifampin 
Risperidone 
Sertraline 
Statins 
Tetracyclines 
Trazodone 
Trovafloxacin 
Valproic acid 
Amoxicillin–clavulanic acid 
Anabolic steroids 
Chlorpromazine 
Clopidogrel 
Oral contraceptives 
Erythromycins 
Estrogens 
Irbesartan 
Mirtazapine 
Phenothiazines 
Terbinafine 
Tricyclics 
Amitriptyline 
Azathioprine 
Captopril 
Carbamazepine 
Clindamycin 
Cyproheptadine 
Enalapril 
Flutamide 
Nitrofurantoin 
Phenobarbital 
Phenytoin 
Sulfonamides 
Trazodone 
Trimethoprim–
sulfamethoxazole 
Verapamil 
Table 1. Pattern of drug-induced liver Injury 
4.1.1 Hepatocellular (hepatitis) injury 
The majority of drugs produce a hepatocellular pattern of injury. Most of these instances are 
asymptomatic and mild. When they are severe, patients on average have symptoms similar 
to those expected in the ones with an acute viral hepatitis. The laboratory features typically 
included a normal complete blood count, although a mild increase in white count may 
occur, and a minority of patients with immunoallergic-type reactions will show a peripheral 
eosinophilia. Given the fact that the underlying pathogenesis involves primarily an 
apoptosis and/or a necrosis of the hepatocytes, the serum aminotransferases levels are 
elevated. For most of the drugs producing an idiosyncratic DILI, the degree of elevation of 
serum aminotransferases is generally less marked than in the cases of intrinsic 
hepatotoxicity caused by acetaminophen, carbon tetrachloride or other halogenated 
hydrocarbons. The serum Alk P is generally normal or mildly elevated (less than twice the 
ULN). Serum total and direct bilirubin are variable. The hepatobiliary imaging shows a 
normal liver or a diffuse homogeneous hepatomegaly. It is very important the lack of 
evidence of the dilatation of the biliary tree or cholecystitis especially when patients are 
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jaundiced. The typical findings on liver biopsy, during an acute injury, are variable and 
greatly dependent upon the causative drug. In most of the instances of a hepatocellular 
injury a rapid improvement in symptoms, signs and laboratory features can occur when the 
medication is discontinued. 
4.1.2 Cholestatic pattern of injury 
The typical manifestations of a cholestatic drug-induced hepatitis are jaundice and itching. 
The classic laboratory features are the elevations in serum Alk P, which is more than twice 
the ULN, and in the serum total and direct bilirubin. Serum aminotransferases are normal or 
only mildly elevated. In general, the hepatobiliary-pancreatic imaging findings show no 
evidence of the biliary dilatation and of the pancreatic abnormalities. The liver is usually 
normal or nearly normal. The typical iter of the cholestatic hepatitis is more protracted than 
in the hepatocellular DILI. In fact, it is not uncommon for signs and laboratory worsening to 
continue after the drug has been stopped, sometimes for a period of 30-60 days. There is a 
gradual improvement thereafter, unless the categories of the drugs are re-administered. 
There are rare instances in which the injury does not resolve but rather goes on to produce 
chronic liver diseases.  
4.1.3 “Mixed” pattern of injury 
The ‘mixed’ pattern, as the name implies, involves hepatocellular and cholestatic 
manifestations. The usual clinical ones are nausea, anorexia, and vomiting when severe; also 
jaundice and itching are present. The typical laboratory findings may include serum 
aminotransferase levels higher than three times the ULN and serum Alk P, total and direct 
bilirubin being more than twice the ULN. The biopsy features for the two types of injury are 
also a mixture of characteristics described above. The general course is longer than in the 
hepatocellular injury, but shorter than in the pure cholestatic DILI. 
4.2 Mechanism of toxicity 
The toxic hepatocellular injury may be classified into two groups: predictable (intrinsic) and 
unpredictable (idiosyncratic) reactions. The predictable drug reaction accounts for 80% of all 
toxicities. Intrinsic hepatotoxins cause predictably a dose-dependent hepatocellular necrosis 
(higher concentrations cause more liver damage) and which can be reproducible in the 
animal models. The latent period between the exposure and the onset of the reaction is brief 
(i.e. hours/days) and varies from person to person. Most cases of DILI hepatotoxicity are 
related to idiosyncratic reactions. The main characteristic of this type of reaction is the 
apparent unpredictability of the liver injury in human beings. The effects tend to be species-
specific and often cannot be reproduced experimentally on the laboratory animals. There is 
no a constant relationship between the dose and the occurrence or severity of the drug 
reaction, and the latent period between the exposure to it and the sensitivity reaction is quite 
variable. Idiosyncrasy may be either metabolic or immunologic/allergic. In the first case, a 
covalent binding of drug metabolites to the cellular structures can damage the cellular 
functions causing the cell death. The immunologic reactions are the hypersensitivity 
reactions to a specific drug. The immunologic response depends upon the interaction of the 
drug and its metabolites with the immune system, with a resultant hepatocyte necrosis and 
apoptosis; this can cause the release of cytokines that can lead to the secondary cell damage 
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or can have immune modulating effects. There is a prompt recurrence of symptoms in 
response to the drug re-challenge of one or two doses.  
5. Histology 
Specific histological patterns of  liver injury caused by a drug-induced damage are discussed 
below. 
5.1 Acute hepatocellular injury 
The landmarks of an acute hepatocellular injury are the portal and the parenchyma 
inflammation and/or necrosis. By definition, fibrosis is absent. Regenerative features such 
as binucleate hepatocytes and thick cell plates are common. Prominent Kupffer cells are 
often present in the sinusoids. The acute hepatocellular injury can result in necrosis affecting 
single (spotty necrosis) or groups of hepatocytes (confluent necrosis). Hepatocellular 
necrosis consists of a ballooning degeneration or apoptosis associated with an infiltration of 
the inflammatory cells and can be zonal or nonzonal, depending upon the offending drug. 
Zonal necrosis is characteristic of compounds with a dose-dependent toxicity, such as 
carbon tetrachloride and acetaminophen (zone 3). Isolated necrosis affecting zones 1 and 2 is 
rare; toxins such as cocaine and ferrous sulfate or phosphorus poisoning typically affect 
zone 1 (periportal), while beryllium has been implicated in zone 2 necrosis. Nonzonal 
necrosis is more often seen with compounds that produce an idiosyncratic injury (i.e. 
phenytoin, methyldopa, isoniazid, and diclofenac). 
 
 
Fig. 1. Acetaminophen toxicity. Hepatocellular necrosis present in a zonal, centrilobular 
pattern; the inflammatory infiltration is minimal 
5.1.1 Fulminant hepatitis 
There are three morphological categories related to ALF. Extensive microvesicular steatosis 
(rare) has been observed with tetracycline and nucleoside analogues such as zidovudine. 
Necrosis with a marked inflammatory activity is the most common pattern seen in the 
idiosyncratic reactions. The confluent necrosis involves most of the liver parenchyma 
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(massive/submassive hepatic necrosis) and the mainly implicated drugs are isoniazid, 
others are antimicrobial agents (sulfonamides, cotrimoxazole, ketoconazole), monoamine 
oxidase inhibitors and anticonvulsants (phenytoin, valproate). Necrosis with little or no 
inflammation is seen with acetaminophen, recreational drugs such as cocaine and 3,4-
methylenedioxymethylamphetamine (MDMA; ecstasy), industrial organic compounds such 
as carbon tetrachloride, and some herbal preparations.  
5.2 Chronic hepatocellular injury 
A progression to chronicity has been reported in 5-10% of DILI and it is higher for the 
cholestatic/mixed injury pattern and can reveal with many forms. A chronic hepatitis with 
negative autoimmune markers presents histological features indistinguishable from the 
chronic viral hepatitis, and a progression to fibrosis can occur. Drugs associated to it include 
lisinopril, sulfonamide, trazodone and chemotherapeutic agents such as uracil, 5-
fluorouracil pro-drug tegafur and tamoxifen. Isolated case reports implicate numerous other 
drugs including phenytoin and the Chinese herb Jin bu huan. Several drugs and herbs (i.e. 
minocycline, nitrofurantoin, diclofenac, fenofibrate, phenytoin, germander, statins, ecstasy) 
can cause a chronic hepatitis that is serologically and morphologically indistinguishable 
from de novo type I of the autoimmune hepatitis (AIH). 
 
 
Fig. 2. Minocycline-induced autoimmune hepatitis. Necroinflammatory activity with several 
plasma cells 
The lipofuscin pigment storage in the hepatocytes has been reported with phenothiazines, 
phenacetin, aminopyrine, and cascara sagrada. An hemosiderin accumulation in the liver 
cells may result from the excessive iron ingestion or the parenteral iron. Phospholipidosis 
is rare. It may develop acutely, but it is more commonly seen after a prolonged 
administration of the offending agent. This condition has been described in the patients 
taking amiodarone, amitriptyline, trimethoprim-sulfamethoxazole, chloroquine. The 
hepatocytes can be seen as foamy as a consequence of phospholipid accumulation in the 
lysosomes. These abnormal, lamellated lysosomes are visible through the electron 
microscopy (Figure 3). 
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Fig. 3. Histological pattern of hepatic phospholipidosis. Presence of lysosomal inclusion 
bodies due to an accumulation of amiodarone 
5.3 Acute cholestasis 
Two forms of this histological pattern of injury can be observed. Canalicular (bland or non-
inflammatory) cholestasis is characterized by bile plugs in the hepatocytes or canaliculi and 
it is more prominent in zone 3. Inflammation and hepatocellular injuries are not detected. 
Drugs causing this type of injury interfere with the hepatocyte secretion of the bile 
components through the bile salt excretory protein (BSEP). The degree of cholestasis is 
characteristic for each drug; typical examples are the anabolic steroids (Figure 4) and the 
oral contraceptives. Hepatocanalicular (cholangiolitic or inflammatory) cholestasis is 
accompanied by a portal inflammation and by only a slight hepatocytes injury, usually 
localized in the zones of the cholestasis. Cholestatic hepatitis is the classic pattern seen with 
macrolide antibiotics such as erythromycin (figure 5) and the antipsychotic agent 
chlorpromazine. This pattern manifests as a mixed-type injury on the liver biochemical tests. 
 
 
Fig. 4. Anabolic-steroid-induced cholestasis. Bile plugs present in the hepatocytes and 
canaliculi without inflammation or hepatocellular damage 
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Fig. 5. Erythromycin-induced cholestatic hepatitis. Features similar to an acute hepatitis, as 
well as bile plugs in the hepatocytes and canaliculi 
5.4 Chronic cholestasis and ductopenia 
Drugs causing long-lasting cholestasis (longer than 3 months) and ductopenia include 
antibiotics (amoxicillin-clavulanic acid, flucloxacillin), antifungals (terbinafine), amiodarone 
(Figure 6). If the disease persists for a few months or further, it can occur a loss of bile ducts 
and an overt ductopenia termed ‘‘vanishing bile duct syndrome’’. A persistent inflammation 
and a bile ductular reaction may also be present. A vanishing bile duct syndrome can be 
triggered by anticonvulsants (carbamazepine, zonisamide), antipsychotics (chlorpromazine, 
sulpiride), NSAIDs (ibuprofen, tenoxicam) and antibiotics (amoxicillin, flucloxacillin, 
clindamycin, trimethoprim-sulfamethoxazole). 
 
 
Fig. 6. Prolonged cholestasis. Persistence of canalicular bile plugs associated with a feathery 
degeneration of the periportal hepatocytes 
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5.5 Granulomatous hepatitis 
At least 60 drugs have been selected to cause hepatic non-caseating granulomas, for instance 
allopurinol, amiodarone, diazepam, diltiazem, isoniazid, sulfonamides and sulfonylureas. 
Unlike in the primary biliary cirrhosis, the granulomas are habitually located in the 
periportal and portal tracts. They can be associated with a hepatocellular injury 
(granulomatous hepatitis) or cholestasis, but are more often silent and it is usually transient. 
The term fibrin-ring granuloma has been used for small granulomas characterized by a ring 
of fibrin around a central fat vacuole. Epithelioid histiocytes are present around the ring of 
fibrin. Fibrin-ring granulomas have been described with allopurinol, BCG vaccination and 
intravescical therapy for carcinoma. Gold salts may lead to the formation of lipogranulomas 
with black pigments. 
 
 
Fig. 7. Fibrin-ring granulomas. Fat vacuole surrounded by a ring of fibrin and epithelioid 
cells 
5.6 Steatosis and steatohepatitis 
Steatosis secondary to drug toxicity may be in the form of medium-sized and large 
droplets (macrovesicular) or small droplets (microvesicular). The term ‘‘large droplet fat’’ 
is used when at least half of the hepatocyte cytoplasm is full of a single lipid vacuole, 
while multiple lipid vacuoles are seen in the small droplet fat. Drugs that can cause 
macrovesicular steatosis include corticosteroids, methotrexate, nifedipine, parenteral 
nutrition, gold, NSAIDs (ibuprofen, indomethacin, sulindac), antihypertensives 
(metoprolol) and chemotherapeutic agents (5-fluorouracil, cisplatin, tamoxifen). An 
exclusive or predominant microvesicular steatosis is the result of mitochondrial injury 
and is observed with aspirin (Reye's syndrome), cocaine, high doses of tetracycline, 
valproic acid and zidovudine. By definition, steatohepatitis is characterized by steatosis, 
lobular inflammation and hepatocellular ballooning (with or without the acidophil bodies 
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or Mallory hyaline) or pericellular fibrosis. A few drugs (particularly amiodarone and 
irinotecan) play a direct aetiological role in the steatohepatitis. Many other drugs 
exacerbate or precipitate steatohepatitis in the presence of other risk factors such as 
obesity and diabetes. 
5.7 Vascular lesions 
The drug-induced hepatic vascular disease is uncommon but can have several 
manifestations. Vascular lesions result from the injury of the endothelium. The hepatic 
sinusoidal obstruction syndrome (veno-occlusive disease) is due to the occlusion of the 
terminal hepatic venules and sinusoids rather than the hepatic veins and inferior vena cava 
that manifests histologically as an endothelial swelling and thrombosis. The resultant 
venous outflow obstruction leads to a sinusoidal dilatation, congestion, hepatocellular 
necrosis, resulting in centrilobular fibrosis. Cytotoxic/chemotherapeutic drugs (i.e. 
oxaliplatin) can cause injury to the sinusoidal endothelial and hepatic stellate cells. Other 
drugs associated with veno-occlusive diseases include pyrrolizidine alkaloids (found in 
herbal remedies), azathioprine, mercaptopurine, vitamin A, tetracycline. 
 
 
Fig. 8. Veno-occlusive disease. Endothelial injury in small hepatic venules leading to 
sinusoidal dilatation and congestion. 
Peliosis is rare and is characterized by multiple, small, dilated blood-filled cavities without 
an endothelial coating in the hepatic parenchyma. It can be caused by several drugs 
including anabolic steroids, arsenic, azathioprine, mercaptopurine, danazol, tamoxifen, 
vitamin A and hydroxyurea. Lesions may resolve with a discontinuation of the offending 
agent. The hepatic venous outflow obstruction is a rare complication that may arise from a 
drug-induced thrombosis of the hepatic veins or of the inferior vena cava. The most well-
known drugs associated with this syndrome are the oral contraceptives and dacarbazine. 
Clinically it manifests as the Budd-Chiari syndrome. 
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Fig. 9. Peliosis. Hepatic parenchyma containing blood-filled cavities without an endothelial 
lining 
6. Diagnostic elements 
DILI is a diagnosis of exclusion that relies on multiple elements in the medical history, 
presentation, laboratory results.  
6.1 Time to onset 
The time to onset (latency) is evaluated from the first day on which the suspected drug(s) 
was taken to the day on which the symptoms or the laboratory test abnormalities are 
manifested. A definition of the exposure to the drug and the hepatic toxicity is not always 
clear because the initial symptoms can be vague and are poorly remembered; the onset of 
the symptoms can occur days or weeks after the medication is stopped; laboratory tests are 
obtained at an arbitrary time. Furthermore, the drug can be stopped and started or given in 
several courses or in different doses and patients may take multiple medications making the 
identification of a single offending agent difficult.  
6.2 Clinical and laboratory features  
The clinical presentation varies from the asymptomatic mild liver test abnormalities to a 
symptomatic acute liver disease. Many drugs can induce asymptomatic high levels of the 
liver enzymes without producing an overt clinical disease. DILI is generally considered 
subclinical if the serum ALT is < 3 times the ULN; it has been described with antibiotics, 
antidepressants, lipid-lowering drugs, sulfonamides, salicylates, sulfonylureas and 
quinidine, generally in fewer than 5-10% of individuals. About 50% of patients receiving 
tacrine for Alzheimer’s disease have shown high ALT levels. This tolerance is also observed 
in 25-50% of the patients taking methyldopa or phenytoin, and it is especially well described 
with isoniazid. When symptomatic, DILI shows a high variability and symptoms as fatigue, 
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nausea, abdominal pain, fever, dark urine, jaundice and itching can be present. Rash, facial 
edema and lymphadenopathy, along with eosinophilia or atypical lymphocytosis, are 
important early features that, when present, point to a hypersensitivity and are typical for 
aromatic anticonvulsants, sulfonamides and allopurinol. Laboratory tests for patients to be 
made include a complete blood cell count, an hepatic and renal function, a total protein and 
an electrophoresis, coagulative parameters and urinalysis. Hepatitis B surface antigen, 
hepatitis C and hepatitis A serology should be performed to exclude an infectious aetiology. 
Anti nuclear antibodies (ANA) and anti smooth muscle antibodies (SMA) tests may help in 
the cases of a possible AIH. 
6.3 De- challenge 
The course of the liver injury after the ending of the suspected drug(s) is considered the de- 
challenge. If a medication causes DILI, its withdrawal should be followed by a clinical 
improvement; however, the liver injury may continue to worsen a few weeks after the 
causative toxic agent is stopped. 
6.4 Risk factors 
- Age: the adults are generally more susceptible to hepatotoxicity than children. Elderly 
people are at a higher risk of a hepatic injury because of the decreased clearance, the 
drug-to-drug interactions, the reduced hepatic blood flow, the variation of the drug 
binding and of the lower hepatic volume. Older age appears to be an important risk 
factor for the development of the hepatic injury in response to isoniazid, but younger 
age appears significant for the valproate-induced liver injury and for the aspirin-
induced Reye’s syndrome.  
- Sex: the women may be more likely to develop the hepatic injury from medications, but 
they are also more likely to take them.  
- Race: the Blacks or African American subjects appear to be more susceptible to 
develop anticonvulsant hypersensitivities and liver injuries, whereas Caucasian 
whites appear to be at an increased risk for developing a flucloxacillin-related liver 
injury.  
- Genetic: the most important susceptibility factor for hepatotoxicity is a genetic 
variability. Genetic polymorphisms have a strong influence on drug metabolism, 
however, are largely medication-specific. For example, polymorphism of the N-
acetyltransferase 2 (NAT-2) gene differentiates fast from slow acetylators; the latter 
have increased their susceptibility to isoniazid toxicity. The human leukocyte antigen 
(HLA)-B*5701 genotype is the major determinant of abacavir and flucloxacillin 
hypersensitivity reactions. Estrogen-induced cholestasis is closely linked to variants in 
adenosine triphosphate–binding cassette B11 (bile salt export pump), and valproate 
toxicity is closely linked to the variants of mitochondrial polymerase gamma (POLG1). 
None of these factors is, however, absolute, and hepatotoxicity can occur in patients 
without these specific markers.  
- Alcohol: it causes depletion of glutathione (hepatoprotective) stores that make the 
person more susceptible to toxicity caused by drugs.  
- Obesity and malnutrition: they are susceptibility factors, particularly in the case of 
acetaminophen, which, when used in malnourished patients, may deplete glutathione. 
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- Others: pregnancy, concomitantly administered medications and an history of drug 
reactions also increase susceptibility. Long-acting drugs may cause more injury than 
shorter-acting drugs. Pre-existing liver diseases and coexisting illnesses may have a 
greater effect on the ability of the patient to recover from the liver injury than on the 
likelihood that it will develop. 
6.5 Exclusion of other causes of a liver injury 
Most of the causality instruments for assessing DILI include results of virological, 
serological and radiological tests. A number of scales to codify causality of drug toxicity into 
objective criteria have been developed. Examples include the CIOMS Roussel-Uclaf 
causality assessment method (RUCAM) scale and the Maria & Victorino (M & V) clinical 
scale. However, they do not address all risk factors in all patients and none of these scales 
are used routinely in the clinical practice. A checklist of minimal required elements in the 
diagnosis of DILI is shown in the table 2. 
 
Patient age (at the time of injury onset) and sex 
Implicated drug, herbal or dietary supplement with generic name, dose and regimen of 
administration 
Date on which the agent was started and stopped (or the duration of therapy) 
If symptoms are present, the pattern and date of onset (or the time from the beginning of 
therapy), the types of symptoms 
Date of the first abnormal laboratory results indicative of injury (or the time from the 
beginning of therapy) 
Previous history or risk factors of the liver disease 
Alcohol use history 
Other medical conditions of importance (pertinent negatives being heart failure, shock, 
sepsis, and parenteral nutrition shortly before the onset of liver injury) 
Other medications taken in the 2 months before the onset of the injury 
Initial ALT, AST, Alk P, GGT, serum bilirubin value 
Prothrombin time or INR 
Eosinophils (number/mcL or %) at the onset of the injury or early in the course of the 
injury 
Selected serial ALT (or AST) values (peak values and values demonstrating recovery) 
Selected serial Alk P (or GGT) values (peak values and values demonstrating recovery) 
Selected serial bilirubin values (peak values and values demonstrating recovery) 
Blood test results to exclude other causes of an acute liver disease  
a. IgM anti-HAV (or negative anti-HAV) 
b. HBsAg and IgM anti-HBc (or negative anti-HBc) 
c. Anti-HCV and HCV RNA 
d. ANA and SMA (and titer if positive) 
Imaging of the liver (type and results) 
Abbreviations: ANA, antinuclear antibody; anti-HBc, antibody to hepatitis B core antigen; 
HAV, hepatitis A virus; HBsAg, hepatitis B surface antigen; IgM, immunoglobulin M; 
SMA, smooth muscle antibody. 
Table 2. Elements necessary for reporting cases of DILI 
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History of previous DILI,  exposure to the drug or similar agents 
Results of serum ALT, Alk P and total bilirubin before the exposure to the agent or onset 
of DILI 
Weight and height expressed as the body mass index  
LDH level at the onset of the injury or early in the course of the injury 
CPK level at the onset of the injury or early in the course of the injury 
Serum albumin and globulin levels at the onset of the injury or early in the course of the 
injury 
IgG level at the onset of the injury or early in the course of the injury 
Anti-HEV or HEV RNA 
Anti-HIV 
IgM anti-CMV or CMV-DNA by PCR 
Heterophil antibody or EBV-DNA by PCR 
If HBsAg is present, anti-HDV and serial HBV DNA levels 
Other autoantibody results such as AMA and anti-LKM 
Date of resolution of the symptoms or duration of the symptoms 
Liver biopsy results 
Results of the re-exposure or challenge 
Abbreviations: AMA, antimitochondrial antibody; CMV, cytomegalovirus; CPK, 
creatinine phosphokinase; EBV, Epstein-Barr virus; ERCP, endoscopic retrograde 
cholangiopancreatography; HBsAg, hepatitis B surface antigen; HDV, hepatitis D virus; 
HEV, hepatitis E virus; IgG, immunoglobulin G; IgM, immunoglobulin M; LDH, lactate 
dehydrogenase; LKM, liver-kidney microsomal; MRCP, magnetic resonance 
cholangiopancreatography; PCR, polymerase chain reaction 
Table 3. Elements not always necessary but supportive of the assessment and helpful in 
reporting some cases of DILI 
6.6 Previous reports of DILI 
An important aspect in assessing DILI is whether the drug, herbal/dietary supplement have 
been previously reported as a causative agent of hepatotoxicity. Except for the most 
common medication with a characteristic pattern of injury, this information is largely 
unknown. A proposal was made to classify drugs with respect to their likelihood of causing 
a liver injury. Thus, agents were placed in five categories based on the number of published 
cases and case series in the literature: (A, known) > 50 cases, (B, rare) 11 to 50 cases, (C, very 
rare) 3 to 10 cases, (D, unproven) < 3 cases and (E, not implicated) not convincingly linked to 
cases of hepatotoxicity; a final category (X, insufficient information) is necessary for those 
agents that have not been adequately assessed (i.e. new drugs) or are too rarely used to 
judge their potential for hepatotoxicity. 
6.7 Re-challenge 
Re-challenge is defined as the intentional or inadvertent re-exposure to a drug believed to 
have caused either a current or a past hepatotoxicity. A positive re-challenge consists of the 
recurrence of the DILI, usually with a shorter latency and a greater severity. While it 
remains the gold standard for the diagnosis of a DILI, the re-challenge is not advised. 
However, a careful re-challenge might be appropriate for some cancer chemotherapeutic 
agents, antiretroviral or antitubercular medications.  
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6.8 Liver biopsy 
The role of a liver biopsy in the diagnostic work-up of DILI is controversial. Although some 
histological features may increase the index of suspicion of DILI, there are none which can 
unequivocally confirm the diagnosis. If the patient demonstrates a rapid improvement in 
the liver tests following the ending of the drug, a routine liver biopsy is not indicated. If the 
patient has an underlying liver disease and ⁄or if AIH is suspected despite negative 
serologies, a liver biopsy can be valuable. A liver biopsy can be helpful when the drug has 
not been previously implicated causing a liver injury, or when the drug reaction has a very 
slow regression. However, the impact of identifying some of these unusual histological 
patterns on management is uncertain and the indication of a liver biopsy depends on the 
course of the liver injury as mentioned above. 
7. Grading severity in DILI 
Severity in DILI can be graded as mild, moderate or severe. Most of the severity scales are 
based on the presence and on the number of symptoms, the height of the liver 
biochemistry, the presence of signs of a hepatic failure and the ultimate outcome, such as 
recovery, chronicity or death. In developing a prospective database of cases, Drug-
Induced Liver Injury Network (DILIN) established a five-point system for grading 
severity. 
 
Score Grade Definition 
1 Mild 
Elevations in serum ALT and/or Alk P levels, but the total 
serum bilirubin level is < 2.5 mg/dL, and INR is < 1.5 
2 Moderate 
Elevations in serum ALT and/or Alk P levels, and the 
serum bilirubin level is ≥ 2.5 mg/dL, or INR is ≥ 1.5 
3 Moderate-severe 
Elevations in serum ALT, Alk P, and bilirubin or INR 
levels, and hospitalization or ongoing hospitalization is 
prolonged because of a DILI episode 
4 Severe 
Elevations in serum ALT and/or Alk P levels, and the total 
serum bilirubin level is ≥ 2.5 mg/dL, and there is at least 
one of the following: 
Hepatic failure (INR ≥ 1.5, ascites, or encephalopathy) 
Other organ failure believed to be due to a DILI event (i.e., 
renal or pulmonary) 
5 Fatal Death or liver transplantation from a DILI event 
 
Table 4. Disease severity scales used in the DILIN prospective study 
8. Prognosis 
The majority of the patients with a symptomatic acute DILI recover completely after the 
discontinuation of the drug(s). First described by Hy Zimmerman (Zimmerman, 1999), the 
drug-induced jaundice (total bilirubin > 2.5 mg⁄dL) was associated with a poor prognosis. 
This observation called Hy’s Law is used by regulatory agencies in the evaluation of the 
www.intechopen.com
 Liver Biopsy in Modern Medicine 
 
134 
investigational drugs showing potential hepatotoxicity during clinical trials. The outcome 
is obviously dependent on the severity of the liver impairment at presentation. For 
example, the prognosis of idiosyncratic DILI patients with ALF, coagulopathy (INR > 1.5) 
and encephalopathy is usually poor without a liver transplantation. Also patients with a 
cholestatic DILI have a significant mortality. The prognosis is also dependent on the 
specific compound involved. For instance, in one series, mortality ranged from 40% with a 
halothane-induced liver injury, whereas all patients with an erythromycin-induced liver 
injury survived. A longer duration of the therapy before the recognition of DILI and a 
continuation of the therapy despite a liver dysfunction seems to increase the risk of 
developing a chronic liver disease. Drugs most frequently associated with chronicity were 
amoxicillin⁄clavulanate, bentazepam and atorvastatin. Patients with a cholestatic liver 
injury develop more frequently a chronic liver injury. Peripheral eosinophilia has been 
shown to have a prognostic importance, in fact it was extremely rare in fatal DILI cases. 
Limited data exist on the impact of histology on the clinical outcome. Recently, in a study 
of patients with a disulfiram-induced liver injury, the hepatic eosinophilic infiltration is 
associated with a good short-term prognosis, whereas hepatocytes dropout or necrosis 
with a poor prognosis. 
9. Treatment of DILI 
Once DILI is suspected, a prompt cessation of drug(s) implicated is obviously the first step 
in the management. At the onset of the reaction, patients with jaundice and who also have 
coagulopathy and/or encephalopathy should be hospitalized. It is important to recognize 
the severity of the liver injury in a patient with jaundice and coagulopathy before the 
development of the encephalopathy. Encephalopathy is a very late sign and after its 
development, a rapid deterioration is often observed. Few specific therapies have been 
shown to be beneficial in clinical trials. Two exceptions are the use of N-acetylcysteine for 
acetaminophen toxicity and L-carnitine for cases of valproic acid overdose. Corticosteroids 
are of unproven benefit for most forms of drug hepatotoxicity, although they may have a 
role in the case of a hypersensitivity syndrome, in the AIH (if it is considered to be induced 
by drugs) and in patients with a severe or progressive liver injury, but data supporting their 
safety and efficacy are lacking. Patients should be followed by serial biochemical 
measurements. 
10. Conclusion 
DILI is a rare but important complication that will continue to be problematic with the 
new drugs coming onto the market. Recent data highlight antibiotics, central nervous 
system agents, herbal/dietary supplements and immunomodulatory drugs as the most 
common causes of DILI in the USA. The limitations of the available instruments to 
measure causality in DILI may be minimized by the use of expert panel opinions, while 
biomarkers of DILI have not been discovered yet. It is the health care system, including 
the physician’s responsibility to monitor and report drug-induced hepatotoxicity. A 
systematic approach should be taken to determine the aetiology of hepatotoxicity and to 
remove the offending agent. New therapies for the drug-induced acute liver failure are 
needed. 
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